Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had receive...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Martínez-Cuadrón, David, Serrano, J, Mariz, José, Gil, Cristina, Tormo, M, Martínez-Sánchez, P, Rodríguez-Arbolí, Eduardo, García-Boyero, R, Rodríguez-Medina, C, Martínez-Chamorro, C, Polo, M, Bergua Burgues, Juan Miguel, Aguiar, Eliana, Amigo, María-Luz, Herrera, Pilar, Alonso-Domínguez, Juan Manuel, Bernal, Teresa, Espadana, A, Sayas, M.J, Algarra, Lorenzo, Vidriales, M.B, Vasconcelos, G, Vives Polo, Susana, Pérez-Encinas, Manuel, López, A, Noriega, V, García-Fortes, M, Chillón, M. Carmen, Rodríguez-Gutiérrez, J.I, Calasanz, M.J, Labrador, Jorge, López, J. A, Boluda, Blanca, Rodríguez-Veiga, R, Martínez-López, J, Barragán, Eva, Sanz, Miguel A, Montesinos, P, Universitat Autònoma de Barcelona. Departament de Medicina
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1-and 5-year OS rates were 25% and 7%. OS was significantly (p